Nano-In
Speratum’s Delivery Edge
A Dual-Polymer RNAi Platform Built for Precision and Power
What is Nano-in™ Drug Delivery?
A Dual-Polymer RNAi Platform Built for Precision and Power
Delivering RNAi molecules into diseased cells—efficiently, safely, and without degradation—is one of the greatest challenges in modern medicine. At Speratum Biopharma, we’ve reimagined drug delivery by building a synthetic, biocompatible dual-polymer system that overcomes the trade-offs faced by current technologies.
Introducing Nano-In™, our proprietary PLGA-PEI hybrid delivery platform that combines the strengths of two distinct materials—polyethylenimine (PEI) and poly(lactic-co-glycolic acid) (PLGA)—to form smart nanoparticles that target tumor cells with high precision..
Thank you USNW for allowing us to use this video
Why Not Just Use One?
Each polymer has its own strengths—but also critical weaknesses. Alone, they fall short. Together, they’re transformative.
PEI (Polyethylenimine)
✅ Strengths: Excellent at condensing RNA and promoting cellular uptake via endosomal escape.
⚠️ Limitations: High molecular weight PEI can be cytotoxic, and low molecular weight PEI alone lacks stability.
PLGA (Poly(lactic-co-glycolic acid))
✅ Strengths: Biocompatible, biodegradable, and FDA-approved for clinical use; protects cargo from degradation.
⚠️ Limitations: Poor at loading or releasing negatively charged RNA molecules on its own.
Why Our Hybrid Approach Wins
By synthetically integrating PEI and PLGA into a dual-polymer nanoparticle, we created a system that is:
Efficient
PEI condenses and protects RNA, while PLGA stabilizes and releases it in a controlled fashion.
Biocompatible
PLGA reduces PEI’s toxicity while enabling safe, systemic administration.
Tumor-targeting:
Engineered surface properties allow for accumulation in solid tumors via EPR effect
Flexible
Allows IV, intratumoral, or localized delivery depending on therapeutic need.
Versatile
Compatible with complex scaffolds like our NoPass™ RNAi constructs
The result? RNAi therapeutics that are more stable, more specific, and more powerful than ever before.
Learn how Nano-in™ is paving the way for next-generation cancer treatments:
Built for Tumors. Built for Versatility.
|
Feature
|
Nano-in
|
Liposomes
|
Viral Vectors
|
|---|---|---|---|
|
Safety
|
Low toxicity, non-immunogenic
|
High immunogenicity, risk of immune responses
|
|
|
Stability
|
Stable at room temperature for 30+ weeks
|
Requires cold-chain logistics
|
Limited stability, requires cryopreservation
|
|
Delivers small RNAs to large plasmids
|
Limited to small or moderate-sized cargo
|
Restricted to specific cargo sizes
|
|
|
Targeting
|
Customizable receptor-mediated targeting
|
Passive or limited targeting
|
Some specificity but risk of off-target effects
|
|
High cost, difficult to scale
|
Built for Tumors. Built for Versatility.
Unlike other platforms tied to liver-only delivery or requiring invasive administration, Speratum’s Nano-In™ platform is designed to go where cancer hides—deep into solid tumors, resistant microenvironments, and hard-to-treat tissues.
When combined with NoPass™ RNAi, our delivery system becomes more than a carrier—it becomes an enabler of curative intent.
What Sets Us Apart?
Smart Design
Not just biocompatible. Algorithmically optimized for disease-specific targeting.
Protection + Potency
Keeps RNAi active longer, with minimal immune stimulation.
Clinical Scalability
Built on FDA-recognized polymers (PLGA), with a clear path to GMP manufacturing.
